慢性乙型肝炎患者血清MMP-2和TIMP-2水平及超声检查指标评估肝纤维化分期意义探讨*

doi:10.3969/j.issn.1672-5069.2019.04.014

摘要/Abstract

摘要： 目的探讨超声检查门静脉指标及血清基质金属蛋白酶-2（MMP-2）和金属蛋白酶组织抑制因子-2（TIMP-2）变化在慢性乙型肝炎（CHB）患者肝纤维化分期中的诊断价值。方法 2014年5月~2018年5月我院收治的CHB患者43例和同期健康体检者40例,使用超声B超检查测定门静脉宽度、脾静脉宽度和脾脏厚度,采用ELISA法检测血清MMP-2和TIMP-2水平,采用微孔板单光子计数仪检测血清透明质酸（HA）、层粘连蛋白（LN）、Ⅳ型胶原蛋白（IV-C）和III前胶原氨基端肽（P III P）水平。常规行肝穿刺活检。结果肝穿组织病理学检查提示,S0~S1患者13例,S2患者11例,S3患者14例和S4患者5例;自S2期到S4期,随着肝纤维化程度的不断加重,患者门静脉宽度、脾静脉宽度和脾脏厚度不断增大,差异具有统计学意义（P<0.05）;S0~1、S2、S3和S4期患者血清MMP-2水平分别为（291.5±35.3） mg/L、（357.7±32.5） mg/L、（446.8±47.1） mg/L和（595.3±85.4） mg/L,血清TIMP-2水平分别为（154.3±28.6） mg/L、（210.7±24.1） mg/L、（255.7±31.9） mg/L和（302.5±74.3） mg/L,均显著高于健康人[分别为（246.5±32.1） mg/L和（126.5±20.1） mg/L,P<0.05];存在显著肝纤维化的CHB患者血清HA、LN、IV-C和P III P水平显著高于健康人（P<0.05）,且随着肝纤维化加重而逐渐升高。结论超声检测门静脉指标联合血清指标检测将有助于对CHB患者肝纤维化程度的判断,对诊断和治疗疗效的判断可能具有指导意义。

关键词: 慢性乙型肝炎, 彩色多普勒超声, 基质金属蛋白酶-2, 基质金属蛋白酶组织抑制因子-2

Abstract: Objective To investigate the diagnostic value of portal vain by ultrasonography and serum matrix metalloproteinase-2 （MMP-2） and tissue inhibitor of metalloproteinase-2（TIMP-2） in patients with chronic hepatitis B （CHB）.Methods Forty-three patients with CHB and 40 healthy controls were enrolled in our hospital between May 2014 and May 2018,and all patients underwent liver biopsy for liver fibrosis staging. B-ultrasound was performed in all subjects,and the width of portal vein, the width of the splenic vein,and the thickness of the spleen were measured. Serum MMP-2 and TIMP-2 levels as well as hyaluronic acid （HA）,laminin （LN）,type IV collagen（IV-C） and III procollagen amino terminal peptide （P III P） were assayed.Results Liver biopsy results showed that there were 13 patients with S0-S1,11 patients with S2,14 patients with S3,and 5 patients with S4;From S2 to S4 with the increasing degree of liver fibrosis,the portal vein width,splenic vein width and spleen thickness increased gradually,and the differences between patients with different liver fibrosis was statistically significant（P<0.05）;Serum MMP-2 levels in patients with S0-1,S2,S3 and S4 were（291.5±35.3） mg/L,（357.7±32.5） mg/L,（446.8±47.1） mg/L and （595.3±85.4） mg/L,and serum TIMP-2 levels were （154.3±28.6）mg/L,（210.7±24.1） mg/L,（255.7±31.9） mg/L and （302.5±74.3） mg/L,significantly higher than（246.5±32.1） mg/L and （126.5±20.1） mg/L（P<0.05） in healthy persons;serum HA,LN,IV-C and P III P levels in patients with significant liver fibrosis were higher than those in healthy control （P<0.05）. Conclusion The examination of portal vain parameters by ultrasonography and serum liver fibrosis determination might help predict the intrahepatic liver fibrosis in patients with CHB.

Key words: Hepatitis B, Ultrasonography, Mmatrix metalloproteinase-2, Tissue inhibitor of metalloproteinase-2

闫瑞斌, 马淑梅, 卓玛, 乔志忠, 刘潇. 慢性乙型肝炎患者血清MMP-2和TIMP-2水平及超声检查指标评估肝纤维化分期意义探讨^*[J]. 实用肝脏病杂志, 2019, 22(4): 506-509.

Yan Ruibin, Ma Shumei, Zhuo Ma, et al. Significance of portal vain parameters by ultrasonography and serum MMP-2 and TIMP-2 detection in evaluation of liver fibrosis in patients with chronic hepatitis B[J]. JOURNAL OF PRACTICAL HEPATOLOGY, 2019, 22(4): 506-509.

参考文献

[1] 刘国旺,唐克诚,李谦,等. 慢性乙型肝炎抗病毒治疗HBeAg血清学转换的预测模型建立. 中华肝脏病杂志,2018,26(9):641-645.
[2] Gerstenmaier JF,Gibson RN.Ultrasound in chronic liver disease. Insights Into Imaging,2014,5(4):441-455.
[3] Bramhall SR,Neoptolemos JP,Stamp GWH,et al.Imbalance of expression of matrix metalloproteinases(MMPs) and tissue inhibitors of the matrix metalloproteinases(TIMPs) in human pancreatic carcinoma. J Pathol,2015,182(3):347-355.
[4] 中华医学会肝病学分会;中华医学会感染病学分会.慢性乙型肝炎防治指南(2015年版).实用肝脏病杂志,2016,19(3):389-400.
[5] 王燕,陈香宇,李娅,等. 血清微小核糖核酸-122在慢性乙型肝炎肝纤维化中的表达及意义. 中华传染病杂志,2018,36(9):533-536.
[6] Zhou Y,Wan Y,Ye ZW,et al.How hepatitis B virus causes cirrhosis and liver cancer. Med Hypoth,2017,108(10):52-53.
[7] Yan LN.Operative techniques in liver resection. Ultrasound elastography in the assessment of liver fibrosis. PLoS One,2013,8(8):e72306.
[8] Calabro SR,Maczurek AE,Morgan AJ,et al.Hepatocyte produced matrix metalloproteinases are regulated by CD147 in liver fibrogenesis. PLoS One,2014,9(7):e90571.
[9] 陶然,黄加权,李小丹,等. 热休克蛋白47-短发夹RNA对日本血吸虫肝纤维化小鼠的体内干预研究. 中华传染病杂志,2014,32(7):7-12.
[10] Cui N,Hu M,Khalil RA.Biochemical and biological attributes of matrix metalloproteinases. Prog Mol Biol Transl Sci,2017,147:1-73.
[11] 陈建泉,张建成,陈林,等. 肝细胞生长因子和转化生长因子-β1对人心房成纤维细胞基质金属蛋白酶-2及组织抑制剂-2表达的影响. 中华心律失常学杂志,2017,21(6):489-495.
[12] Gu X,Fu M,Ding Y,et al.TIMP-3 expression associates with malignant behaviors and predicts favorable survival in HCC.PLoS One,2014,9(8):e106161.
[13] Tiziana L,Claudia M,Ilaria P,et al.Liver fibrosis in HCV monoinfected and HIV/HCV coinfected patients:Dysregulation of matrix metalloproteinases(MMPs) and their tissue inhibitors TIMPs and effect of HCV protease inhibitors. Int J Mol Sci,2016,17(4):455-466.
[14] Khokha R,Murthy A,Weiss A.Metalloproteinases and their natural inhibitors in inflammation and immunity. Nat Rev Immunol,2013,13(9):649-665.
[15] Pineda JA.Combined use of aspartate aminotransferase,platelet count and matrix metalloproteinase 2 measurements to predict liver fibrosis in HIV/hepatitis C virus-coinfected patients. HIV Med,2015,12(1):14-21.
[16] Julio C,Eulalia VG,Tomás SZ,et al.Matrix metalloproteases and their tissue inhibitors in non-alcoholic liver fibrosis of human immunodeficiency virus-infected patients. J Med Virol,2017,6(2):18-27.
[17] Kurzepa J,Madro A,Czechowska G,et al.Role of MMP-2 and MMP-9 and their natural inhibitors in liver fibrosis,chronic pancreatitis and non-specific inflammatory bowel diseases. Hepatobiliary Pancreat Dis Int,2014,13(6):570-579.
[18] Okazaki I,Noro T,Tsutsui N,et al.Fibrogenesis and carcinogenesis in nonalcoholic steatohepatitis (NASH):involvement of matrix metalloproteinases(MMPs) and tissue inhibitors of metalloproteinase (TIMPs). Cancers (Basel),2014,6(3):1220-1255.
[19] Munsterman ID,Kendall TJ,Khelil N,et al.Extracellular matrix components indicate remodelling activity in different fibrosis stages of human non-alcoholic fatty liver disease. Histopathology,2018,73(4):612-621.
[20] Toyoda H,Kumada T,Kiriyama S,et al.Higher hepatic gene expression and serum levels of matrix metalloproteinase-2 are associated with steatohepatitis in non-alcoholic fatty liver diseases. Biomarkers,2013,18(1):82-87.

慢性乙型肝炎患者血清MMP-2和TIMP-2水平及超声检查指标评估肝纤维化分期意义探讨^*

Significance of portal vain parameters by ultrasonography and serum MMP-2 and TIMP-2 detection in evaluation of liver fibrosis in patients with chronic hepatitis B

PDF (PC)

可视化

摘要/Abstract

引用本文

使用本文

参考文献

相关文章 15

编辑推荐

Metrics

本文评价

[1]	朱凌云, 张茂海, 崔莎莎, 张秋萍. 慢性乙型肝炎患者血清IL-12、IL-18水平和外周血单个核细胞FOXp3基因水平研究^*[J]. 实用肝脏病杂志, 2019, 22(6): 816-819.
[2]	石莹莹, 王元喜. 替比夫定联合阿德福韦酯治疗慢性乙型肝炎患者效果及其对肾功能的影响^*[J]. 实用肝脏病杂志, 2019, 22(6): 820-823.
[3]	闵峰, 黄文琪, 吴卫兵, 张丽, 范荣华. 慢性乙型肝炎患者血清脂肪细胞因子水平变化及其临床意义^*[J]. 实用肝脏病杂志, 2019, 22(6): 824-827.
[4]	张迎明, 申爽, 田飞, 孙园园. IFNL4和IL-28B基因多态性检测评估慢性乙型肝炎患者抗病毒治疗应答价值分析^*[J]. 实用肝脏病杂志, 2019, 22(6): 828-831.
[5]	李传杰, 徐静, 王亮亮, 潘劲劲, 刘波. 恩替卡韦治疗慢性乙型肝炎患者血清HBsAg变化与病毒学应答的相关性研究[J]. 实用肝脏病杂志, 2019, 22(6): 928-929.
[6]	赵协山, 伍春瑢, 王春峰, 余积洁, 何青. 替诺福韦联合安络化纤丸治疗HBeAg阴性慢性乙型肝炎患者疗效及其血清肝纤维化指标的变化研究*[J]. 实用肝脏病杂志, 2019, 22(5): 644-647.
[7]	涂杰霞, 王安娜, 廖若汐. 干扰素α-2b与聚乙二醇干扰素α-2a治疗慢性乙型肝炎患者疗效比较研究*[J]. 实用肝脏病杂志, 2019, 22(5): 648-651.
[8]	高伟, 侯勇. 肝脏硬度值检测诊断慢性乙型肝炎患者肝组织纤维化的效能分析*[J]. 实用肝脏病杂志, 2019, 22(5): 652-655.
[9]	白一春, 邓霁红, 梅小平. 影响聚乙二醇干扰素α-2b治疗慢性乙型肝炎患者疗效的多因素分析^*[J]. 实用肝脏病杂志, 2019, 22(4): 490-493.
[10]	程华, 鞠辉, 宋德顺, 李伟. 慢性乙型肝炎患者血清血管生成素样蛋白2和高尔基体蛋白73水平变化及其诊断显著肝纤维化的效能分析^*[J]. 实用肝脏病杂志, 2019, 22(4): 494-497.
[11]	李高明, 吕必华. 菖郁逍遥散治疗慢性乙型肝炎伴抑郁患者负性情绪和中医证候积分的变化^*[J]. 实用肝脏病杂志, 2019, 22(4): 498-501.
[12]	余英芳, 温生宝. 应用磁共振DWI单指数、双指数和拉伸指数模型参数评估慢性乙型肝炎患者肝纤维化程度效能研究^*[J]. 实用肝脏病杂志, 2019, 22(4): 502-505.
[13]	张亚飞, 叶珺, 谢琴秀, 邹桂舟, 李家斌, 李旭, 张振华. 不同医院无创性肝纤维化指标预测慢性乙型肝炎患者肝纤维化效能差异分析^*[J]. 实用肝脏病杂志, 2019, 22(4): 510-513.
[14]	彭思璐, 刘冰, 孙宏, 林剑, 潘志颖, 邓存良. HBV相关慢加急性肝衰竭患者预后及其影响因素分析^*[J]. 实用肝脏病杂志, 2019, 22(4): 545-548.
[15]	卢西梅, 康燕飞, 宋智勇, 朱乔. 彩色多普勒超声检查诊断肝移植术后胆道并发症价值分析^*[J]. 实用肝脏病杂志, 2019, 22(4): 589-592.